Cresco Labs (CRLBF) Stock Price, News & Analysis

Company Overview

Cresco Labs, Inc. (OTCMKTS:CRLBF) is a leading vertically integrated cannabis operator in the United States. Founded in 2013 and headquartered in Chicago, the company manages the entire cannabis supply chain from cultivation and extraction to product manufacturing and retail distribution. Cresco Labs is structured to deliver a broad range of cannabis offerings to consumers while maintaining regulatory compliance in each state it serves.

The company’s core business activities encompass cultivating premium cannabis flower, producing oils and concentrates, and formulating a diverse portfolio of branded consumables. Under its flagship brands—such as Cresco, Reserve, and Good News—the company offers products that include pre-rolls, vape cartridges, edibles, and topicals. Cresco Labs also operates Sunnyside dispensaries, a consumer-focused retail banner designed to provide an upscale, consistent shopping experience.

With licenses and operations spanning numerous states—including Illinois, California, Massachusetts, Florida, Pennsylvania and Michigan—Cresco Labs has built one of the largest footprints in the U.S. cannabis market. Through strategic acquisitions, such as the purchase of Origin House and VidaCann, the company has strengthened its wholesale distribution network and expanded its ability to serve both medical and adult-use markets. Cresco Labs’ infrastructure includes state-of-the-art cultivation facilities, a manufacturing campus in Naperville, Illinois, and a robust logistics framework that supports seamless supply across licensed markets.

Leadership at Cresco Labs is spearheaded by co-founder and CEO Charlie Bachtell, whose experience in both the financial and cannabis sectors has guided the company’s rapid growth. The executive team combines expertise in regulatory affairs, agriculture, manufacturing and retail operations, with a strong emphasis on compliance, sustainability and community engagement. Cresco Labs continues to prioritize research and development, aiming to innovate new delivery methods and product formulations that address consumer preferences and medical needs.

Key Stats

• Today's Range: $0.48 to $0.54
• 50-Day Range: $0.43 to $0.98
• 52-Week Range: $0.43 to $2.05
• Volume: 63,474 shs
• Average Volume: 622,667 shs
• Market Capitalization: $247.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Cresco Labs Stock Analysis - MarketRank™

Cresco Labs scored higher than 15% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Cresco Labs.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cresco Labs are expected to grow in the coming year, from ($0.20) to ($0.05) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cresco Labs is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cresco Labs is -2.10, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cresco Labs has a P/B Ratio of 0.64. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.15% of the float of Cresco Labs has been sold short.

Short Interest Ratio / Days to Cover

Cresco Labs has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cresco Labs has recently increased by 29.34%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cresco Labs does not currently pay a dividend.

Dividend Growth

Cresco Labs does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.15% of the float of Cresco Labs has been sold short.

Short Interest Ratio / Days to Cover

Cresco Labs has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cresco Labs has recently increased by 29.34%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.63

News Sentiment

Cresco Labs has a news sentiment score of 0.63. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cresco Labs this week, compared to 2 articles on an average week.

Search Interest

2 people have searched for CRLBF on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Cresco Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -86% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cresco Labs insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 0.05% of the stock of Cresco Labs is held by institutions.

CRLBF Stock Analysis - Frequently Asked Questions

How have CRLBF shares performed this year?

Cresco Labs' stock was trading at $0.9137 on January 1st, 2025. Since then, CRLBF shares have decreased by 44.8% and is now trading at $0.5046.

How were Cresco Labs' earnings last quarter?

Cresco Labs Inc. (OTCMKTS:CRLBF) issued its earnings results on Friday, May, 30th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by $0.01. The firm earned $165.76 million during the quarter, compared to the consensus estimate of $164.37 million. Cresco Labs had a negative trailing twelve-month return on equity of 21.77% and a negative net margin of 11.86%.

How do I buy shares of Cresco Labs?

Shares of CRLBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/30/2025
• Today: 7/08/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:CRLBF
• CIK: 1832928
• Web: www.crescolabs.com
• Phone: 312-929-0993
• Fax: N/A
• Employees: 2,900
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.44 million
• Net Margins: -11.86%
• Pretax Margin: -3.89%
• Return on Equity: -21.77%
• Return on Assets: -6.00%

Debt

• Debt-to-Equity Ratio: 1.63
• Current Ratio: 2.75
• Quick Ratio: 1.98

Sales & Book Value

• Annual Sales: $724.34 million
• Price / Sales: 0.34
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.79 per share
• Price / Book: 0.64

Miscellaneous

• Outstanding Shares: 491,020,000
• Free Float: N/A
• Market Cap: $246.98 million
• Optionable: Not Optionable
• Beta: 1.40